CD8A and neoplasm: Further, the combination of G0S2 inhibitor (NS-3-008) and anti-PD-1 antibody treatment significantly suppressed tumor volume(Figure 6F) and promoting CD8+ T cells function (Figures 6G, H).These findings suggest that G0S2 may serve as a metabolic target that influences immune responses.